Clinical trials: Locally Advanced Rectal Carcinoma
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
- Trial name
- NCT02132858
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fox Chase Cancer Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00551421
- Testing
- pertuzumab, cetuximab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk…
- Trial name
- NCT04495088
- Testing
- mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant)
- Where
- Germany
- Volunteers
- 215 people
- Sponsor
- Ralf Hofheinz
Neoadjuvant Treatment, Rectal Cancer
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Cetuximab, Radiotherapy
- Trial name
- NCT04923620
- Testing
- cetuximab+mFOLFOX6, short-course radiotherapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Rectal Neoplasms
Assessment of Complete Response MRI Criterion After Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Standard care for locally advanced rectal cancer consists in a neoadjuvant therapy followed by surgery. Morbidity and mortality remain high after rectal surgery, and often linked with quality of life impairment.
- Trial name
- NCT05534841
- Where
- France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Rectal Cancer
Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in Locally Advanced Rectal Cancer
Compared to postoperative chemotherapy combined with radiotherapy, preoperative chemotherapy combined with radiotherapy shows higher sphincter preservation rate and lower local recurrence rate in locally advanced rectal cancer.
- Trial name
- PCAR (NCT03601156)
- Testing
- intraarterial chemoembolization, intravenous chemotherapy
- Where
- 3 sites in China
- Volunteers
- 204 people
- Sponsor
- Third Military Medical University
Locally Advanced Rectal Cancer (LARC)
AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy
This study aims to better understand how body composition, inflammation, and nutrition affect how rectal cancer responds to treatment.
- Trial name
- CINR-AI (NCT07049627)
- Testing
- Total Neoadjuvant Therapy (TNT)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Ankara Etlik City Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Rectal Cancer
Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial
This study is a prospective, single-arm clinical trial with a dose-reduction design, which is expected to enrol 18 patients with locally advanced rectal cancer with pMMR status.
- Trial name
- RADIANT (NCT07774754)
- Testing
- Drug：sintilimab, Drug：Capecitabine, Drug：Suvemcitug
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Rectal Neoplasms
Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
Neoadjuvant chemoradiation (CRT), is considered the standard treatment of locally advanced rectal cancer with a positive impact on locoregional control and survival.However, patients with T4 rectal cancer show high risk of local…
- Trial name
- NCT02723253
- Testing
- Radiotherapy, Tom-OX
- Volunteers
- 18 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rectal Cancer
Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
The National Comprehensive Cancer Network (NCCN) guidelines recommend trimodality treatment for patients with middle and low LARC with neoadjuvant chemoradiotherapy (NA-CRT), surgical resection with TME, plus additional…
- Trial name
- NCT05274945
- Testing
- Radiotherapy, consolidation chemotherapy, TME or APR
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Alexandria University
Rectal Cancer
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
The goal of this Phase 2 trial is to evaluate a neoadjuvant treatment mode for locally advanced rectal cancer (LARC), consisting of radiotherapy and concurrent Trifluridine/Tipiracil (TAS-102).
- Trial name
- TASLARC (NCT05965531)
- Testing
- Trifluridine/Tipiracil, intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer
In this study, investigators utilize a radiomics prediction model to predict the tumor response to neoadjuvant chemoradiotherapy (nCRT) before the nCRT is administered for patients with locally advanced rectal cancer (LARC).
- Trial name
- MRAI-pCR (NCT04273477)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Locally Advanced Rectal Cancer
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
The study evaluate the addition of Irinotecan in neoadjuvant chemoradiation. Half of participants will receive capecitabine alone together with neoadjuvant CRT, followed by a cycle of XELOX, while the other will receive…
- Trial name
- CinClare (NCT02605265)
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Fudan University
Rectal Cancer
BReak Interval Delayed Surgery for Gastrointestinal Extraperitoneal Rectal Cancer
This is a randomized multicentric clinical trial in patients affected by resectable rectal cancer, cT2N1-2, cT3N0-2, MRF -, aiming to evaluate the impact of the interval between chemoradiotherapy and surgery on the pathological…
- Trial name
- BRIDGE (NCT03581344)
- Testing
- Repetition of Re-staging
- Where
- Italy
- Volunteers
- 148 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Immune-related Adverse Event, Neoadjuvant Therapy
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
This study aims to explore the optimal number of cycles of PD-1 monotherapy required at minimum, under the premise of ensuring pathological complete response (pCR) among patients with dMMR/MSI-H rectal cancer.
- Conditions
- Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
- Trial name
- NCT06613165
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Locally Advanced Rectal Cancer (LARC)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
This is a phase II, multicenter, randomized (2:1) controlled, clinical trial to evaluate the preliminary efficacy and safety of consolidation chemotherapy (XELOX) plus dostarlimab after standard long-course CRT (ARM A) compared…
- Trial name
- IMMUNOSTAR (NCT07381777)
- Testing
- XELOX (Capecitabine and Oxaliplatin), Dostarlimab
- Where
- 30 sites in Italy
- Volunteers
- 270 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica